Yungaowa Wu

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV

Min Gu, Yilan Jin, Jun Zhao, 2021, Pharmacogenomics and personalized medicine.

Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting.

Jun Zhao, Xiaojun Bai, Quanfu Li, 2019, Current problems in cancer.

Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting

Jun Zhao, Xiaojun Bai, Quanfu Li, 2018, Open medicine.

Treatment and survival status of patients with EGFR mutation-positive stage IV lung adenocarcinoma: five-year follow-up results in the Ordos Area of Inner Mongolia, China

Jun Zhao, Xiaojun Bai, G. Jin, 2018, Oncology and Translational Medicine.

A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy

G. Jin, Wenjuan Wang, Juan Zhao, 2024, Journal of cancer research and clinical oncology.

Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study

Yilan Jin, Jun Zhao, Quanfu Li, 2022, Supportive Care in Cancer.